Paper No. ____ Filed: February 24, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC, INNOPHARMA INC., INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and MYLAN INC., Petitioner,

V .

SENJU PHARMACEUTICAL CO., LTD., BAUSCH & LOMB, INC., and BAUSCH & LOMB PHARMA HOLDINGS CORP.

Patent Owner.

Case IPR2015-00902 (Patent 8,669,290 B2) Case IPR2015-00903 (Patent 8,129,431 B2)¹

PETITIONER'S AMENDED NOTICE OF CROSS-EXAMINATION OF DR. STEPHEN G. DAVIES, D.PHIL



¹ A word-for-word identical paper has been filed in each proceeding identified in the heading. IPR2015-01871 has been joined with IPR2015-00903 and includes Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. in addition to the parties identified above.

Case IPR2015-00902 (Patent 8,669,290 B2) Case IPR2015-00903 (Patent 8,129,431 B2)

INC., INNOPHARMA LICENSING LLC, INNOPHARMA INC.,

Pursuant to 37 C.F.R. § 42.53, Petitioners INNOPHARMA LICENSING,

INNOPHARMA LLC, MYLAN PHARMACEUTICALS INC., and MYLAN

INC., ("Petitioner" or "InnoPharma"), by and through its attorneys, will conduct a

cross-examination by deposition of Dr. Stephen G. Davies, D.Phil regarding his

declarations submitted in IPR2015-00902 and IPR2015-00903. Dr. Davies' cross-

examination will take place, as agreed by counsel for the parties, on February 29,

2016, commencing at 9:00 a.m. (local time), at the offices of Finnegan, Henderson,

Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, DC

20001-4413. Counsel for Patent Owner has represented that Dr. Davies is willing

to appear at the time and location indicated above.

The cross-examination will take place before a Notary Public or other officer

authorized by law to administer oaths. It will be recorded using at least audiotape

and/or stenographic means. InnoPharma also intends to video record the cross-

examination of Dr. Davies. The arrangements for the reporter and videographer

will be made by counsel for Petitioners.

Date: February 24, 2016

|Jitendra Malik|

Jitendra Malik (Reg. No. 55823)

Alston & Bird LLP

4721 Emperor Boulevard, Suite 400

Durham, North Carolina 27703

DOCKET A L A R M 1

Case IPR2015-00902 (Patent 8,669,290 B2) Case IPR2015-00903 (Patent 8,129,431 B2)

Telephone: 919-862-2200

Fax: 919-862-2260 Jitty.Malik@alston.com

Lead Counsel for Petitioner InnoPharma Licensing Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., and Mylan Inc.



CERTIFICATION OF SERVICE

The undersigned certifies that on the 24th day of February, 2016, a copy of the foregoing Petitioner's Amended Notice of Cross-Examination of Dr. Stephen G. Davies, D.Phil was served via email directed to counsel of record for the Patent Owner and counsel of record for Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc. at the following:

Patent Owner

Bryan C. Diner bryan.diner@finnegan.com

Justin J. Hasford justin.hasford@finnegan.com

Joshua L. Goldberg
Joshua.goldberg@finnegan.com

Petitioners Lupin Ltd. and Lupin Pharmaceuticals Inc.

Deborah H. Yellin DYellin@Crowell.com

Jonathan Lindsay JLindsay@Crowell.com

Respectfully submitted,

Alston & Bird LLP

By: /Jitendra Malik/

Jitendra Malik, Ph.D. Reg. No. 55823 Alston & Bird LLP



Case IPR2015-00902 (Patent 8,669,290 B2) Case IPR2015-00903 (Patent 8,129,431 B2) 4721 Emperor Blvd., Suite 400 Durham, NC 27703-8580 jitty.malik@alston.com

Bryan Skelton, Ph.D.
Reg. No. 50893
Alston & Bird LLP
4721 Emperor Blvd., Suite 400
Durham, NC 27703-8580
bryan.skelton@alston.com

Lance Soderstrom
Reg. No. 65405
Alston & Bird LLP
90 Park Avenue
15th Floor
New York, NY 10016-1387
lance.soderstrom@alston.com

Hidetada James Abe Reg. No. 61,182 Alston & Bird LLP 333 South Hope Street 16th Floor Los Angeles, CA 90071 james.abe@alston.com

Attorneys for Petitioners InnoPharma Licensing, Inc., InnoPharma Licensing LLC, InnoPharma Inc., InnoPharma LLC, Mylan Pharmaceuticals Inc., and Mylan Inc.

